Earnings And ProfitabilityManagement's organic EBITDA growth framework supports expectations of improving profitability and margin expansion through operating efficiencies and greater scale.
Pharmacy Segment GrowthAdoption of generics, biosimilars, and increased limited-distribution drug launches is likely to raise pharmacy revenue per script and strengthen gross margins.
Service Diversification And Strategic ExpansionInvestments in rare and orphan drug services, expanded infusion capabilities, and targeted home health acquisitions broaden service offerings and create multiple growth avenues beyond core oncology.